ImmuPharma PLC Given Buy Rating at Panmure Gordon (IMM)
ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating restated by equities researchers at Panmure Gordon in a research report issued on Friday, StockRatingsNetwork.com reports. They currently have a GBX 150 ($2.40) price target on the stock. Panmure Gordon’s price target indicates a potential upside of 103.46% from the company’s current price.
Shares of ImmuPharma PLC (LON:IMM) opened at 70.00 on Friday. ImmuPharma PLC has a 52-week low of GBX 34.15 and a 52-week high of GBX 77.50. The stock has a 50-day moving average of GBX 51.07 and a 200-day moving average of GBX 43.43.
ImmuPharma plc is a drug discovery and development company. The Company focuses on developing drugs, based on peptide therapeutics, to treat medical conditions such as autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.